Find Topic

Transport & Logistics

Interview with Michael Frost of COAG Reform Council

We have the opportunity to interview with Michael Frost, Executive Director of Capital Cities Strategic Planning Systems, COAG Reform Council. 1) Australian cities are facing major challenges in the near future. Population figures are projected to rise significantly within the next few decades. Urban congestion is inhibiting economic growth and is estimated to cost billions…

29 Apr 2011, by Informa Insights


Rising patient numbers and novel products are set to drive growth in the Chinese antidiabetics market

Melbourne, March 23, 2011 – Driven by the growing diabetic population and the improved healthcare insurance coverage implemented as part of the country's 2009 healthcare reform, the value of the overall diabetes drugs market in China will triple from $0.7bn in 2009 to $2.1bn in 2019, according to a new report from independent market analyst,…

25 Mar 2011, by Informa Insights


The Chinese hepatitis B market is set to triple by 2019

Melbourne, March15, 2011 – Fueled by the world’s largest hepatitis B patient pool, uptake of new therapies such as PEGylated interferons and Viread (tenofovir), and the government’s latest healthcare reforms, the Chinese hepatitis B market is set to continue its recent growth, and to triple in size by 2019, according to the latest analysis by…

15 Mar 2011, by Informa Insights


Battle against MRSA to net pharma industry US$2bn

Melbourne, 7th March 2011 - A number of new and expensive hospital brands targeting serious infections caused by multidrug-resistant bacteria, particularly MRSA*, will launch over the next decade. These will generate revenues totalling nearly US$2bn by 2019, according to independent market analyst Datamonitor.** However, the forecasted upside provided by these pipeline products will be insufficient…

7 Mar 2011, by Informa Insights


Will Australian Pharma ever be the same again?

Melbourne, 22nd February 2011 - The Australian pharmaceutical industry landscape is set to dramatically alter as a result of government changes to the Pharmaceutical Benefits Scheme (PBS), suggests independent market analyst, Datamonitor. Datamonitor’s outlook for the future includes withdrawn products, a struggling generics sector and wholesaler reorganization, as PBS reforms take effect. Erin Brady, Australian…

23 Feb 2011, by Informa Insights


Breast cancer cases on the rise in Japan

Melbourne, 18th February 2011. The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13% over the next decade, finds independent healthcare analyst, Datamonitor.* However, in Japan, breast cancer incidence rates will rise by approximately 24% to 2019 to reach 56,400 cases, compared to 45,600…

18 Feb 2011, by Informa Insights


Diabetes pipeline cannot reverse cardiovascular and metabolic market decline

Melbourne, 10th February 2011 - Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, finds independent market analyst Datamonitor.* Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets** will peak in 2011 and then begin to decline, with total sales falling from $105bn in…

10 Feb 2011, by Informa Insights


Can India become a biosimilar powerhouse?

Melbourne, 8th February 2011 - Indian manufacturers are ideally placed to capitalise on the growing biosimilars market, according to independent market analyst Datamonitor. Although the biosimilars market is in its infancy, Datamonitor research suggests that Indian manufacturers are well positioned to capitalise on the future growth of this market both domestically and internationally. Alistair Sinclair,…

8 Feb 2011, by Informa Insights


Rapidly deteriorating growth for Pharma

Melbourne, 21st January 2011. Growth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor. Between 2003 and 2009, theses same companies enjoyed robust sales growth at a compound annual growth rate (CAGR) of 7.1%. Sharp declines in branded sales following…

21 Jan 2011, by Informa Insights


Stigma remains over Major Depressive Disorder

Melbourne, 12th January 2011 - Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor*. Daniel Chancellor, healthcare analyst at Datamonitor, comments: “This is due to the stigma that is…

12 Jan 2011, by Informa Insights
Page  of 137

Get all the latest on Informa news and events

Informa Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more

Subscribe to Insights

Join Our Newsletter
Informa Insights

Stay up-to-date with all the latest
updates, upcoming events & more.